Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data
Open Access
- 5 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (10) , 1046-1054
- https://doi.org/10.1634/theoncologist.2008-0075
Abstract
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.This publication has 23 references indexed in Scilit:
- Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival AdvantageThe Oncologist, 2008
- Mechanisms Underlying the Development of Androgen-Independent Prostate CancerClinical Cancer Research, 2006
- Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinomaCancer, 2005
- Therapeutic options in androgen‐independent prostate cancer: building on docetaxelBJU International, 2005
- Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate CancerOncology, 2005
- Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen FailureJournal of Clinical Oncology, 2005
- The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical ProstatectomyJournal of Urology, 2003
- Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomyProstate Cancer and Prostatic Diseases, 2000
- Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?Medical Hypotheses, 1990
- Parameters of mortality in human populations with widely varying life spansStatistics in Medicine, 1983